Metabolism/Glycosylation Inhibitor

WP1122 is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG.  Based on pre-clinical testing, WP1122 enables increased cellular uptake of 2-DG, increased drug half-life and, importantly, an increased ability to cross the blood brain barrier, enabling greater 2-DG uptake in the brain. Our approach was inspired by the same principle that distinguishes morphine from heroin. Heroin is chemically the diacetyl ester of morphine. While morphine has a limited ability to cross the blood brain barrier (making it a good candidate for pain killing without impairing mental function), its diacetyl form, heroin, has the ability to accumulate in the brain by 10 to 100-fold more than morphine. Once across the blood brain barrier, the acetyl groups shown in this chemical diagram are cleaved off by natural enzyme esterases, leaving pure morphine to accumulate in the brain.

Ongoing Phase 1a Clinical Study:

Phase 1a

Single center study in the United Kingdom of orally delivered WP1122 in healthy volunteers designed to determine a safe and tolerable dose for potential use in future trials in patients with COVID-19 or other similarly structured viruses, as well as various oncology indications.

Key Highlights:

Granted Orphan Drug Designation for GBM

Received IND Clearance to Conduct a Phase 1 Study

Prodrug of glucose decoy enables improved drug-like properties

Targets glycolysis and glycosylation, limiting viral infectivity and replication

Additional Applications in Oncology:

Glioblastoma (GBM) Brain Tumors

Pancreatic Cancer


Our Clinical Studies

Sign Up For Alerts